US › Healthcare

Filana Therapeutics, Inc. (FLNA)

US · Healthcare · Biotechnology

$0.70-7.89%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-8.6M

EPS

$-0.18

EPS estimate

$-0.22

EPS came in at -0.18 against a street estimate of -0.22 — a beat of 18.2%.

Key statistics

Market cap

$36.8M

Forward P/E

151.5

P/B

0.78

Book value

$1.32

EPS (TTM)

$-0.87

52-week high

$4.69

52-week low

$0.67

50-day MA

$0.86

200-day MA

$1.44

Beta

-0.66

Analyst view

Analysts rate Filana Therapeutics, Inc. a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $6.50.

Shareholding

Insiders

2.05%

Institutions

26.81%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	4.09%
Two Sigma Investments LLC	3.54%
Marshall Wace Asset Management Ltd	3.31%
BlackRock Inc	3.01%
Geode Capital Management, LLC	1.27%
D. E. Shaw & Co LP	1.00%
GMT Capital Corp	0.93%
Renaissance Technologies Corp	0.81%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Filana Therapeutics, Inc. — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.